Residual Apolipoprotein B Elevation Despite PREVENT ‐Guided LDL ‐C Goal Attainment Among Adults Without Known Atherosclerotic Cardiovascular Disease (ASCVD)
Authors' conclusion
Among U.S. adults without known ASCVD who attained PREVENT risk-stratified LDL-C goals, residual ApoB elevation was common and strongly associated with triglyceride elevation.
Study context
- Population
- US adults aged 30–79 years without known ASCVD, 10-year PREVENT-ASCVD risk ≥3%, who attained PREVENT risk-stratified low-density lipoprotein cholesterol (LDL-C) goals (National Health and Nutrition Examination Survey (NHANES) 2005–2016)of 3857 with risk ≥3%
- Participants
- 908 adults
- Exposure
- Triglycerides 150-400 mg/dL vs <150 mg/dL
- Outcome
- Prevalence of residual ApoB elevation (ApoB ≥90 mg/dL for PREVENT-ASCVD risk 3% to <10%; ≥70 mg/dL for risk ≥10%)
Methodological detailssurvey-weighted analyses, NHANES 2005-2016
- Survey-weighted analyses
- NHANES 2005-2016
Main finding
As reported in the abstract
Residual ApoB elevation among LDL-C goal attainers
Residual apolipoprotein B (ApoB) elevation, n
128
Weighted prevalence
17.7%
95% CI 14.5%–21.4%
Observational data: associations, not effects.
Further findings
Prevalence of residual ApoB elevation by TG
P < 0.001
| Outcome | aOR (95% CI) | P value | |
|---|---|---|---|
| Prevalence of residual ApoB elevation by TGMultivariable logistic regression | 15.87 (8.28–30.41) | P < 0.001 | |
| 0.050.21520Adjusted odds ratio (log scale) |
- Prevalence of residual ApoB elevation by TG: consistent across exploratory subgroups and robust in sensitivity analyses
Other factors associated with residual ApoB elevation
- Higher odds with PREVENT-ASCVD risk ≥10%, obesity, metabolic syndrome and CKM stages 2-4
Original publication
Residual Apolipoprotein B Elevation Despite PREVENT ‐Guided LDL ‐C Goal Attainment Among Adults Without Known ASCVD. Diabetes Obes Metab. Published 9 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →